24th May 2016 08:37
LONDON (Alliance News) - Silence Therapeutics PLC on Tuesday said David Ellam has been appointed as its new chief financial officer, with effect from July 18.
Ellam is the former Europe, Middle East and Africa finance director at US biotechnology firm BioMarin Pharmaceuticals Inc and is the former finance chief of UK pharmaceutical company Plethora Solutions PLC.
He will replace Timothy Freeborn, who will leave his current role after Silence's annual general meeting on June 17 to move to Berlin. In the German capital, he will move to the role of managing director of Silence Therapeutics GmbH, the firm's German arm.
Silence Therapeutics shares were untraded on Tuesday, having last traded at 112.50 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L